Article
FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.
Molecular cancer therapeutics - 1 Jun 2017
Larrosa-Garcia Maria, Baer Maria R
Abstract excerpt
The receptor tyrosine kinase fms-like tyrosine kinase 3 (FLT3), involved in regulating survival, proliferation, and differentiation of hematopoietic stem/progenitor cells, is expressed on acute myeloid leukemia (AML) cells in most patients. Mutations of FLT3 resulting in constitutive signaling are common in AML, including internal tandem duplication (ITD) in the juxtamembrane domain in 25% of patients and point...
Topics
- Animals
- Antineoplastic Combined Chemotherapy Protocols
- Clinical Trials as Topic
- Drug Evaluation, Preclinical
- Drug Resistance, Neoplasm
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Protein Binding
- Protein Interaction Domains and Motifs